Fewer nivolumab doses with ipilimumab appear effective in unresectable melanoma

The first two doses of nivolumab with ipilimumab appeared to drive efficacy and toxicity of the combination among certain patients with melanoma, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program. To address this, Postow and colleagues conducted a phase 2 study in which patients received the same dosing regimen as in CheckMate 067 but, after the second dose of combination therapy, they included an early tumor assessment to identify patients who had already responded to treatment. Gino In, MD USC Norris Comprehensive Cancer Center Keck School of Medicine of USC Disclosure: In reports consultant/advisory roles with Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences and Novartis.